US 12,358,973 B2
Transthyretin antibodies and uses thereof
Michael Fassler, Ness Ziona (IL); and Jacob George, Tel Aviv (IL)
Assigned to MOR RESEARCH APPLICATIONS LTD., Ramat Gan (IL)
Filed by Mor Research Applications Ltd., Ramat Gan (IL)
Filed on Jun. 10, 2024, as Appl. No. 18/738,824.
Application 18/738,824 is a continuation of application No. 17/255,796, granted, now 12,006,357, previously published as PCT/IB2019/055416, filed on Jun. 26, 2019.
Claims priority of provisional application 62/690,116, filed on Jun. 26, 2018.
Prior Publication US 2025/0002568 A1, Jan. 2, 2025
Int. Cl. C07K 16/18 (2006.01); A61K 49/00 (2006.01); A61P 9/00 (2006.01); G01N 33/68 (2006.01)
CPC C07K 16/18 (2013.01) [A61K 49/0008 (2013.01); A61P 9/00 (2018.01); G01N 33/6893 (2013.01); C07K 2317/14 (2013.01); C07K 2317/76 (2013.01)] 20 Claims
OG exemplary drawing
 
1. An antibody or antigen-binding fragment thereof capable of binding human transthyretin (TTR), wherein the antibody or antigen-binding fragment thereof comprises a complementary determining region (CDR) H1 comprising the amino acid sequence set forth in SEQ ID NO: 8, a CDR H2 comprising the amino acid sequence set forth in SEQ ID NO: 9, a CDR H3 comprising the amino acid sequence set forth in SEQ ID NO: 10, a CDR L1 comprising the amino acid sequence set forth in SEQ ID NO: 11, a CDR L2 comprising the amino acid sequence set forth in SEQ ID NO: 12, and a CDR L3 comprising the amino acid sequence set forth in SEQ ID NO: 6.